Trials / Completed
CompletedNCT05338723
Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Tanta University · Academic / Other
- Sex
- Female
- Age
- 25 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the possible role of rosuvastatin in protection against cardiotoxicity in HER2 positive breast cancer patients receiving doxorubicin sequential with trastuzumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin 20mg | 20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months). |
Timeline
- Start date
- 2020-09-15
- Primary completion
- 2023-09-15
- Completion
- 2023-09-15
- First posted
- 2022-04-21
- Last updated
- 2024-02-28
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05338723. Inclusion in this directory is not an endorsement.